ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ATHE / dividends
GRCE (32) SCYX (28) VERU (30) NSRX (26) ⌘ Pro Terminal →

Alterity Therapeutics Limited (ATHE) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.09 -3.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.07

Alterity Therapeutics Limited (ATHE) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $39.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ATHE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ATHE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Alterity Therapeutics Limited (NASDAQ: ATHE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $2.09 (-3.24% 1D, market cap $39.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ATHE ranks #375 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ATHE compare to GRCE and SCYX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATHE carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GRCE (Grace Therapeutics Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -18.9%, cap $40.8M) and SCYX (SCYNEXIS Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $37.5M). Among the 5-stock peer group, ATHE leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ATHE?
▼

For Alterity Therapeutics Limited (ATHE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #375 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.07 (-0.77%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.7% Base Target
$6 Bull$2 Base$2 Bear
📬 FREE ATHE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATHE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY ATHE SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($1.1M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
53
Grade C-$2.85-16.8% Next Q
Q2 (-2Q)
50
Grade C-$2.37-9.7% Next Q
Q3 (-1Q)
48
Grade D$2.14-2.3% Next Q
Current
45
Grade D$2.09-6.3% Hist 90D α
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATHE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATHE currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.40) and Max Pain ($2.19) forces dealer call-delta covering toward $6.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATHE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ATHE Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATHE)

  • ✓Walkthrough of ATHE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ATHE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.76%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.23H $2.23L $2.09C $2.09VOL 9.1K
RES: $3.87SUP: $1.79SMA50: $3.40SMA200: $3.97
$6.16$5.04$3.91$2.79$1.66RES $3.87SUP $1.79$2.092026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATHE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATHE Butterfly Map → + Track ATHE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ATHE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATHE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ATHE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATHE)

Health Care Rank #375 of 1015 ⚔️ GRCE vs ATHE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATHE vs. GRCE, SCYX, VERU, NSRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Alterity Therapeutics Limited (ATHE) ranks #375 by composite RQD confidence (45/100, grade D) and #770 by equity capitalization ($39.3M). Within this direct 5-issuer industry benchmark cohort, ATHE leads on earnings valuation at N/A trailing P/E, while GRCE leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. ATHE currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ATHE ACTIVE
Alterity Therapeutics Limited
D 45/100 — — — -3.24% $39.3M Benchmark Subject
GRCE
Grace Therapeutics Inc.
E 32/100 — — -18.9% -6.70% $40.8M /grce-vs-athe →
SCYX
SCYNEXIS Inc.
E 28/100 — — -35.0% +1.06% $37.5M /scyx-vs-athe →
VERU
Veru Inc.
E 30/100 — — -35.0% -1.37% $37.3M /veru-vs-athe →
NSRX
Nasus Pharma Ltd.
E 26/100 — — -35.0% +4.21% $36.0M /nsrx-vs-athe →

2. ATHE Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Alterity Therapeutics Limited (ATHE) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $39.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ATHE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATHE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Alterity Therapeutics Limited (NASDAQ: ATHE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $2.09 (-3.24% 1D, market cap $39.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ATHE ranks #375 in composite RQD confidence.

How does ATHE compare to GRCE and SCYX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATHE carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GRCE (Grace Therapeutics Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -18.9%, cap $40.8M) and SCYX (SCYNEXIS Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $37.5M). Among the 5-stock peer group, ATHE leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ATHE?

For Alterity Therapeutics Limited (ATHE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #375 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ATHE trading relative to its 50-day, 200-day, and 52-week technical levels?

ATHE last traded at $2.09 (-3.24% on volume of 6,062 shares), positioning the stock -38.53% below its 50-day simple moving average ($3.40) and -47.36% below its 200-day simple moving average ($3.97). Across its 52-week range of $2.01 to $5.89, ATHE sits at the 2.1% percentile with a 14-day RSI of 27.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.83 to $2.35).

Direct Sub-Reports: ATHE RQD Cockpit ATHE 12M Forecast ATHE Earnings & Move ATHE Dividends & DRIP ATHE Insiders & 13F ATHE Whale Options ATHE Profit Sankey ATHE News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

ATHE — Alterity Therapeutics Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Alterity Therapeutics Limited (ATHE) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $2.09 (-3.24% 1D, market capitalization $39.3M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Alterity Therapeutics Limited (ATHE) is a NASDAQ-listed issuer...0B. —: product lines, customers, and revenue model.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.01 – $5.89 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ATHE carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can ATHE sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $5.89 52-week high?
  • Key Question #3: How sensitive is ATHE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ATHE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alterity Therapeutics Limited (ATHE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ATHE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ATHE Bull vs. Bear Conversation Board — What's Your Call at $2.09?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ATHE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ATHE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $2.85 (+31.9%)
📌 Pinned Debate

Forensic balance-sheet pillar scores 13 / 20 with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5.

Long ATHE at $2.16 targeting $2.85. Forensic balance-sheet pillar scores 13 / 20 with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5.. Institutional whale score is 3/20 and the risk/reward vs. the $2.01 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

@MultipleCompression Shorting a 3/20 institutional whale-flow stock at $2.16 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $1.71 (-20.8%)
Spot @ $2.16

ROIC and FCF yield are both 0% and whale 13F flow scores only 3 / 20 in the Roarable RQD rating.

Sitting on the sidelines or leaning short ATHE above $2.16. ROIC and FCF yield are both 0% and whale 13F flow scores only 3 / 20 in the Roarable RQD rating.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $5.89.

LIVE TAPE